

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

October 2021

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a large, stylized graphic of white and grey wavy lines on a grey background.

PHARMAC  
TE PĀTAKA WHAIORANGA

# Contents

Summary of decisions effective 1 October 2021 .....	3
Section H changes to Part II .....	6
Index .....	11

## Summary of decisions

### EFFECTIVE 1 OCTOBER 2021

- Betamethasone valerate (Betnovate) lotn 0.1%, 50 ml – price increase and addition of PSS
- Cetomacrogol with glycerol (ADE) crm with glycerol 10%, 500 ml and 1,000 ml – to be delisted 1 January 2022
- Cisplatin (DBL Cisplatin) inj 1 mg per ml, 100 ml vial – price increase and addition of PSS
- Diltiazem hydrochloride (Cardizem CD) cap long-acting 180 mg and 240 mg – new listing and addition of HSS
- Diltiazem hydrochloride (Apo-Diltiazem CD) cap long-acting 180 mg and 240 mg – to be delisted 1 February 2022
- Furosemide [frusemide] (IPCA-Frusemide) tab 40 mg – new listing and addition of HSS
- Furosemide [frusemide] (Apo-Furosemide) tab 40 mg – to be delisted 1 March 2022
- Glipizide (Minidiab) tab 5 mg – price increase and addition of PSS
- Hepatic oral feed (Heparon Junior) powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 g, can, 400 g – new presentation listing
- Hepatic oral feed (Heparon Junior) powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can (Pharmacode 2431645) – to be delisted 1 March 2022
- High fat formula (KetoCal 3:1 (Unflavoured)) powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per 100 g, can, 300 g – new presentation listing
- High fat formula (Ketocal 3:1 (unflavoured)) powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can, 300 g – presentation to be delisted 1 April 2022
- Irinotecan hydrochloride (Accord) inj 20 mg per ml, 5 ml vial – new listing and addition of PSS
- Irinotecan hydrochloride (Irinotecan Actavis 100) inj 20 mg per ml, 5 ml vial – to be delisted 1 March 2022
- Isotretinoin (Oratane) cap 5 mg, 10 mg and 20 mg – price increase and addition of PSS
- Levonorgestrel (Postinor-1) tab 1.5 mg – addition of HSS
- Mesalazine (Asamax) tab EC 500 mg – to be delisted 1 March 2022
- Metformin hydrochloride (Metformin Mylan) tab immediate-release 500 mg and 850 mg – new listing and addition of HSS

## Summary of decisions – effective 1 October 2021 (continued)

- Metformin hydrochloride (Apotex) tab immediate-release 500 mg and 850 mg – to be delisted 1 March 2022
  - Metoprolol tartrate (IPCA-Metoprolol) tab 50 mg and 100 mg – new listing and addition of HSS
  - Metoprolol tartrate (Apo-Metoprolol) tab 50 mg and 100 mg – to be delisted 1 March 2022
  - Modafinil (Modavigil) tab 100 mg – price decrease and addition PSS
  - Nadolol (Nadolol BNM) tab 40 mg and 80 mg – new listing and addition of HSS
  - Nadolol (Apo-Nadolol) tab 40 mg and 80 mg – to be delisted 1 March 2022
  - Neostigmine metisulfate (Max Health) inj 2.5 mg per ml, 1 ml ampoule – new listing and addition of PSS
  - Neostigmine metisulfate (AstraZenaca) inj 2.5 mg per ml, 1 ml ampoule – to be delisted 1 March 2022
  - Nepafenac (Ilevro) eye drops 0.3%, 3 ml – to be delisted 1 November 2021
  - Nifedipine (Mylan Italy (24 hr release)) tab long-acting 30 mg – new listing
  - Norethisterone (Noriday 28) tab 350 mcg – price increase and addition of PSS
  - Oestradiol valerate (Progynova) tab 2 mg (Pharmacode 2619423) – new Pharmacode listing
  - Oestradiol valerate (Progynova) tab 2 mg (Pharmacode 2450461) – Pharmacode to be delisted 1 April 2022
  - Paracetamol (Noumed Paracetamol) tab 500 mg-bottle pack – change of HSS start date
  - Palbociclib (Ibrance) tab 75 mg, 100 mg and 125 mg – new presentation listing
  - Palbociclib (Ibrance) cap 75 mg, 100 mg and 125 mg – to be delisted 1 March 2022
  - Povidone-iodine (Riodine) soln 10%, 100 ml – price increase and addition of PSS
  - Propranolol tab 10 mg (Drofate) and tab 40 mg (IPCA-Propranolol) – new listing and addition of HSS
  - Propranolol (Apo-Propranolol) tab 10 mg and 40 mg – to be delisted 1 March 2022
  - Quinapril with hydrochlorothiazide tab 10 mg with hydrochlorothiazide 12.5 mg (Accuretic 10) and tab 20 mg with hydrochlorothiazide 12.5 mg (Accuretic 20) – price increase and addition of PSS
-

## Summary of decisions – effective 1 October 2021 (continued)

- Salbutamol (Ventolin) oral liq 400 mcg per ml, 150 ml – price increase and addition of PSS
- Sodium fusidate [fusidic acid] tab 250 mg, 36 tab pack – new pack size listing
- Sodium fusidate [fusidic acid] tab 250 mg, 12 tab pack – to be delisted 1 March 2022
- Tacrolimus (Zematop) oint 0.1%, 30 g – new listing and addition of HSS
- Tocilizumab (Actemra) inj 20 mg per ml, 4 ml, 10 ml and 20 ml vial – amended restriction criteria
- Upadacitinib (RINVOQ) tab 15 mg – new listing

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 October 2021

### ALIMENTARY TRACT AND METABOLISM

6	MESALAZINE (delisting) Tab EC 500 mg ..... 49.50	100	Asamax
	Note – Asamax tab EC 500 mg to be delisted 1 March 2022.		
11	GLIPIZIDE (↑ price and addition of PSS) Tab 5 mg – <b>5% DV Mar-22 to 2024</b> ..... 4.58	100	<b>Minidiab</b>
11	METFORMIN HYDROCHLORIDE (brand change and addition of HSS) Tab immediate-release 500 mg – <b>1% DV Mar-22 to 2024</b> ..... 14.74	1,000	<b>Metformin Mylan</b>
	Tab immediate-release 850 mg – <b>1% DV Mar-22 to 2024</b> ..... 11.28	500	<b>Metformin Mylan</b>
	Note – Apotex tab immediate-release 500 mg and 850 mg to be delisted 1 March 2022.		

### CARDIOVASCULAR SYSTEM

41	QUINAPRIL WITH HYDROCHLOROTHIAZIDE (↑ price and addition of PSS) Tab 10 mg with hydrochlorothiazide 12.5 mg – <b>5% DV Mar-22 to 2024</b> ..... 4.10	30	<b>Accuretic 10</b>
	Tab 20 mg with hydrochlorothiazide 12.5 mg – <b>5% DV Mar-22 to 2024</b> ..... 5.25	30	<b>Accuretic 20</b>
45	METOPROLOL TARTRATE (brand change and addition of HSS) Tab 50 mg – <b>1% DV Mar-22 to 2024</b> ..... 5.66	100	<b>IPCA-Metoprolol</b>
	Tab 100 mg – <b>1% DV Mar-22 to 2024</b> ..... 7.55	60	<b>IPCA-Metoprolol</b>
	Note – Apo-Metoprolol tab 50 mg and 100 mg to be delisted 1 March 2022.		
45	NADOLOL (brand change and addition of HSS) Tab 40 mg – <b>1% DV Mar-22 to 2024</b> ..... 19.19	100	<b>Nadolol BNM</b>
	Tab 80 mg – <b>1% DV Mar-22 to 2024</b> ..... 30.39	100	<b>Nadolol BNM</b>
	Note – Apo-Nadolol tab 40 mg and 80 mg to be delisted 1 March 2022.		
46	NIFEDIPINE (new listing) Tab long-acting 30 mg ..... 4.78	14	Mylan Italy (24 hr release)
45	PROPRANOLOL (brand change and addition of HSS) Tab 10 mg – <b>1% DV Mar-22 to 2024</b> ..... 7.04	100	<b>Drofate</b>
	Tab 40 mg – <b>1% DV Mar-22 to 2024</b> ..... 8.75	100	<b>IPCA-Propranolol</b>
	Note – Apo-Propranolol tab 10 mg and 40 mg to be delisted 1 March 2022.		

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 October 2021 (continued)

46	DILTIAZEM HYDROCHLORIDE (brand change and addition of HSS)			
	Cap long-acting 180 mg – 1% DV Mar-22 to 2024 .....	7.00	30	<b>Cardizem CD</b>
	Cap long-acting 240 mg – 1% DV Mar-22 to 2024 .....	9.30	30	<b>Cardizem CD</b>
	Note – Apo-Diltiazem CD cap long-acting 180 mg and 240 mg to be delisted 1 February 2022.			
47	FUROSEMIDE [FRUSEMIDE] (brand change and addition of HSS)			
	Tab 40 mg – 1% DV Mar-22 to 2024 .....	8.00	1,000	<b>IPCA-Frusemide</b>
	Note – Apo-Furosemide tab 40 mg to be delisted 1 March 2022.			

## DERMATOLOGICALS

56	ISOTRETINOIN (↑ price and addition of PSS)			
	Cap 5 mg – 5% DV Mar-22 to 2024 .....	11.26	60	<b>Oratane</b>
	Cap 10 mg – 5% DV Mar-22 to 2024 .....	18.75	120	<b>Oratane</b>
	Cap 20 mg – 5% DV Mar-22 to 2024 .....	26.73	120	<b>Oratane</b>
57	CETOMACROGOL WITH GLYCEROL (delisting)			
	Crm 90% with glycerol 10% .....	2.35	500 ml	ADE
		3.10	1,000 ml	ADE
	Note – ADE crm 90% with glycerol 10%, 500 ml and 1,000 ml to be delisted 1 January 2022.			
58	BETAMETHASONE VALERATE (↑ price and addition of PSS)			
	Lotn 0.1% – 5% DV Mar-22 to 2024 .....	25.00	50 ml	<b>Betnovate</b>
59	TACROLIMUS (new listing and addition of HSS)			
	→ Oint 0.1% – 1% DV Mar-22 to 2023 .....	33.00	30 g	<b>Zematop</b>
	Restricted Initiation Dermatologist or paediatrician Both: 1 Patient has atopic dermatitis on the face; and 2 Patient has at least one of the following contraindications to topical corticosteroids: periorificial dermatitis, rosacea, documented epidermal atrophy or documented allergy to topical corticosteroids.			

## GENITO-URINARY SYSTEM

62	LEVONORGESTREL (addition of HSS)			
	Tab 1.5 mg – 1% DV Mar-22 to 2022 .....	4.95	1	<b>Postinor-1</b>
62	NORETHISTERONE (↑ price and addition of PSS)			
	Tab 350 mcg – 5% DV Mar-22 to 2024 .....	12.25	84	<b>Noriday 28</b>

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 October 2021 (continued)

### HORMONE PREPARATIONS

67	OESTRADIOL VALERATE (Pharmacode change)			
	Tab 2 mg.....	12.36	84	Progynova
	Note – Pharmacode 2619423 is a new listing and Pharmacode 2450461 to be delisted 1 April 2022.			

### INFECTIONS

82	SODIUM FUSIDATE [FUSIDIC ACID] (pack size change)			
	→ Tab 250 mg.....	67.85	36	Fucidin
	Note – Fucidin tab 250 mg, 12 tab pack to be delisted 1 March 2022.			

### MUSCULOSKELETAL SYSTEM

98	NEOSTIGMINE METILSULFATE (brand change and addition of PSS)			
	Inj 2.5 mg per ml, 1 ml ampoule – <b>5% DV Mar-22 to 2024</b> .....	33.81	10	<b>Max Health</b>
	Note – AstraZeneca inj 2.5 mg per ml, 1 ml ampoule, 50 ampoule pack to be delisted 1 March 2022.			

### NERVOUS SYSTEM

112	PARACETAMOL (change of HSS date)			
	Tab 500 mg - bottle pack – <b>1% DV Dec-21 Feb-22 to 2024</b> .....	17.92	1,000	<b>Noumed Paracetamol</b>
129	MODAFINIL (↓ price and addition of PSS)			
	→ Tab 100 mg – <b>5% DV Mar-22 to 2024</b> .....	29.13	60	<b>Modavigil</b>

### ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

137	IRINOTECAN HYDROCHLORIDE (brand change and addition of PSS)			
	Inj 20 mg per ml, 5 ml vial – <b>5% DV Mar-22 to 2024</b> .....	52.57	1	<b>Accord</b>
	Note – Irinotecan Actavis 100 inj 20 mg per ml, 5 ml vial to be delisted 1 March 2022.			
141	CISPLATIN (↑ price and addition of PSS)			
	Inj 1 mg per ml, 100 ml vial – <b>5% DV Mar-22 to 2024</b> .....	29.66	1	<b>DBL Cisplatin</b>
144	PALBOCICLIB (presentation change)			
	→ Tab 75 mg.....	4,000.00	21	Ibrance
	→ Tab 100 mg.....	4,000.00	21	Ibrance
	→ Tab 125 mg.....	4,000.00	21	Ibrance
	Note – Ibrance cap 75 mg, 100 mg and 125 mg to be delisted 1 March 2022.			

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.



	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 October 2021 (continued)

160	UPADACITINIB (new listing) → Tab 15 mg.....	1,271.00	28	RINVOQ
	Restricted			
	Initiation – Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept)			
	Rheumatologist			
	<i>Limited to 6 months treatment</i>			
	All of the following:			
	1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and			
	2 Either:			
	2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or			
	2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and			
	3 Either:			
	3.1 The patient is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor; or			
	3.2 Both:			
	3.2.1 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the Section H rules; and			
	3.2.2 Either:			
	3.2.2.1 The patient has experienced intolerable side effects from rituximab; or			
	3.2.2.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis.			
	Continuation – Rheumatoid Arthritis			
	Rheumatologist			
	<i>Re-assessment required after 6 months</i>			
	Either:			
	1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or			
	2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.			
197	TOCILIZUMAB (amended restriction criteria – new criteria shown only) → Inj 20 mg per ml, 4 ml vial .....	220.00	1	Actemra
	→ Inj 20 mg per ml, 10 ml vial .....	550.00	1	Actemra
	→ Inj 20 mg per ml, 20 ml vial .....	1,100.00	1	Actemra
	Restricted			
	<b>Indication – moderate to severe COVID-19*</b>			
	<i>Therapy limited to 1 dose</i>			
	All of the following:			
	1 Patient has confirmed (or probable) COVID-19; and			
	2 Oxygen saturation of <92% on room air, or requiring supplemental oxygen; and			
	3 Patient has significantly increased laboratory markers of systemic inflammation (eg CRP, PCT or ferritin); and			
	4 Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated; and			
	5 Tocilizumab is to be administered at doses no greater than 8 mg/kg IV for a maximum of one dose.			
	Note: Indications marked with * are unapproved indications.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 October 2021 (continued)

### RESPIRATORY SYSTEM AND ALLERGIES

213	SALBUTAMOL (↑ price and addition of PSS) Oral liq 400 mcg per ml – 5% DV Mar-22 to 2024 .....	40.00	150 ml	<b>Ventolin</b>
-----	--	-------	--------	-----------------

### SENSORY ORGANS

219	NEPAFENAC (delisting) Eye drops 0.3% .....	13.80	3 ml	Ilevro
-----	---	-------	------	--------

Note – Ilevro eye drops 0.3% to be delisted 1 November 2021.

### VARIOUS

227	POVIDONE-IODINE (↑ price and addition of PSS) Soln 10% – 5% DV Mar-22 to 2024 .....	4.15	100 ml	<b>Riodine</b>
-----	--	------	--------	----------------

### SPECIAL FOODS

242	HEPATIC ORAL FEED (presentation change) → Powder 12 g protein, 56 g carbohydrate and 22 g fat per 100 g, can .....	78.97	400 g	Heparon Junior
-----	--	-------	-------	----------------

Note – Pharmacode 2615568 is a new listing and Heparon Junior powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can, 400 g (Pharmacode 2431645) to be delisted 1 March 2022.

247	HIGH FAT FORMULA (presentation change) → Powder 15.4 g protein, 7.2 g carbohydrate and 68.6 g fat per 100 g, can .....	35.50	300 g	Ketocal 3:1 (Unflavoured)
-----	--	-------	-------	------------------------------

Note – Pharmacode 2610590 is a new listing and Ketocal 3:1 (unflavoured) powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can, 300 g (Pharmacode 2431637) to be delisted 1 April 2022.

# Index

## Pharmaceuticals and brands

### A

Accuretic 10 .....	6
Accuretic 20 .....	6
Actemra.....	9
Asamax .....	6

### B

Betamethasone valerate .....	7
Betnovate.....	7

### C

Cardizem CD.....	7
Cetomacrogol with glycerol .....	7
Cisplatin.....	8

### D

DBL Cisplatin .....	8
Diltiazem hydrochloride .....	7
Drofate.....	6

### F

Frusemide.....	7
Fucidin .....	8
Furosemide [Frusemide].....	7
Fusidic acid.....	8

### G

Glipizide.....	6
----------------	---

### H

Heparon Junior .....	10
Hepatic oral feed .....	10
High fat formula .....	10

### I

Ibrance .....	8
Ilevro .....	10
IPCA-Frusemide.....	7
IPCA-Metoprolol.....	6
IPCA-Propranolol .....	6
Irinotecan hydrochloride .....	8
Isotretinoin .....	7

### K

Ketocal 3:1 (Unflavoured).....	10
--------------------------------	----

### L

Levonorgestrel .....	7
----------------------	---

### M

Mesalazine.....	6
Metformin hydrochloride .....	6

Metformin Mylan.....	6
Metoprolol tartrate.....	6
Minidiab.....	6
Modafinil.....	8
Modavigil.....	8
Mylan Italy (24 hr release).....	6

### N

Nadolol .....	6
Nadolol BNM.....	6
Neostigmine metilsulfate .....	8
Nepafenac .....	10
Nifedipine.....	6
Norethisterone .....	7
Noriday 28.....	7
Noumed Paracetamol.....	8

### O

Oestradiol valerate.....	8
Oratane.....	7

### P

Palbociclib .....	8
Paracetamol.....	8
Postinor-1.....	7
Povidone-iodine .....	10
Progynova .....	8
Propranolol .....	6

### Q

Quinapril with hydrochlorothiazide .....	6
--	---

### R

RINVOQ .....	9
Riodine .....	10

### S

Salbutamol.....	10
Sodium fusidate [Fusidic acid] .....	8

### T

Tacrolimus.....	7
Tocilizumab .....	9

### U

Upadacitinib.....	9
-------------------	---

### V

Ventolin .....	10
----------------	----

### Z

Zematop .....	7
---------------	---

New Zealand  
Permit No. 478



Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

If Undelivered, Return To: PO Box 10254, Wellington 6143, New Zealand